Bayer
Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer
January 31, 2020Medical Communications, Research and Development Bayer, orion, pharma
Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen …
NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns
January 20, 2020Sales and Marketing Bayer, Cancer, NICE, Vitravki
UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …
Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery
January 10, 2020Medical Communications Bayer, Exscientia, oncology
Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology. …
Bayer and MSD’s chronic heart failure drug meets main goal at Phase 3
November 19, 2019Manufacturing and Production, Research and Development Bayer, MSD, pharma, vericiguat
MSD and Bayer have made it known that their jointly-developed soluble guanylate cyclase (sGC) stimulator vericiguat met its primary endpoint …
Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy
September 24, 2019Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma
Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …
Four perspectives from life sciences companies on multichannel engagement
August 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma
By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …
Bayer buys BlueRock Therapeutics for $600 million
August 9, 2019Medical Communications Bayer, BlueRock, acquisitions, cell therapies, pharma
Bayer has entered into an agreement to fully acquire engineered cell therapy firm BlueRock Therapeutics in a deal worth $600 …
Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation
July 30, 2019Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …
Bayer’s Gadavist becomes first FDA-approved drug for MRI in coronary artery disease patients
July 16, 2019Manufacturing and Production, Sales and Marketing Bayer, FDA, Gadavist, coronary artery disease, pharma
The FDA has awarded approval to Bayer’s Gadavist (gadobutrol) injection, the company confirmed.
FDA expands indication for Eylea to cover all stages of diabetic retinopathy
May 14, 2019Manufacturing and Production Bayer, Eylea, FDA, Regeneron, approval, pharma
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy. Regeneron chief scientific …
Bayer VP elected to two of the firm’s executive committees
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment
Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …
Takeda ordered to pay Bayer $155.19 million over patent infringement
February 6, 2019Research and Development Baxalta, Bayer, Nektar Therapeutics, Takeda, adynovate
A US court has ordered Takeda Pharmaceutical’s Baxalta unit to pay German firm Bayer AG $155.19 million for infringement of …
Top Ten most popular articles on Pharmafile.com this week!
December 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cancer, Diagnostics, Sanofi, Takeda, brexit
Takeda’s acquisition of Shire finally got the go-ahead this week as 88% of shareholders voted in favour of French CEO …
Bayer to cut 12,000 jobs by 2025
December 6, 2018Business Services, Manufacturing and Production, Sales and Marketing Bayer, Germany, Jobs, manfucaturing, monsanto, production
German pharma giant Bayer is set to cut 12,000 jobs by 2025 as part of a plan to focus on …
Latest content
